Maintenance therapy in non-small cell lung cancer
Authors:
- Monica Di BattistaMBMonica Di Battista
- Giovanna CavalloGCGiovanna Cavallo
- Marco BartolottiMBMarco Bartolotti
- Alba A BrandesABAlba A Brandes
- 31 May 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 15 (7) , 839-846
Abstract
Several randomized trials have investigated the role of maintenance treatment for patients with advanced non-small cell lung cancer (NSCLC) not progressed after completion of first-line chemotherapy, with good performance score (PS) and no persistent chemotherapy-induced toxicity. Two separate strategies have been developed: the immediate use of non-cross-resistant drug (switch maintenance or early second-line therapy) or the continuation of platinum partner alone (continuation maintenance) or in combination with other drug (combination maintenance). Here we discuss how the benefits demonstrated in these studies may change clinical practice (in terms of potential toxicity and costs) and reflect on factors that may identify subgroups of patients who might benefit from maintenance therapy in general, and which maintenance therapy specifically.Keywords
This publication has 38 references indexed in Scilit:
- Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient dataThe Lancet Oncology, 2014
- Treatment of Stage IV Non-small Cell Lung CancerChest, 2013
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2011
- Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Radiofrequency Ablation of Inoperable Non-Small Cell Lung CancerJournal of Thoracic Oncology, 2007
- Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancerBritish Journal of Cancer, 2006
- Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or ObservationJournal of Clinical Oncology, 2003
- Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2002
- Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and CisplatinJournal of Clinical Oncology, 2001